Expression analysis of maspin in invasive ductal carcinoma of breast and modulation of its expression by curcumin in breast cancer cell lines

Chemico-Biological Interactions

Volumn 183, Issue 3, 2010, Pages 455-461

  Prasad, Chandra P ^a,b   Rath, Gayatri ^a   Mathur, Sandeep ^b   Bhatnagar, Dinesh ^a   Ralhan, Ranju ^b,c,d  

^a SAFDARJUNG HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; Curcumin; Invasive ductal carcinoma; Maspin; MCF 7; MDA MB 231

Indexed keywords

CURCUMIN; MASPIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MUTANT; RNA TRANSLATION; UPREGULATION; WILD TYPE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CURCUMIN; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; SERPINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 74149094916     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.11.019     Document Type: Article

References (51)

1. Zou Z., Anisowicz A., Hendrix M.J., Thor A., Neveu M., Sheng S., Rafidi K., Seftor E., and Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263 (1994) 526-529
2. Benarafa C., and Remold-O'Donnel E. The ovalbumin serpins revisited: perspective from the chicken genome of clade B serpin evolution in vertebrates. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 11367-11372
3. Hojo T., Akiyama Y., Nagasaki K., Maruyama K., Kikuchi K., Ikeda T., Kitajima M., and Yamaguchi K. Association of maspin expression with the malignancy grade and tumor vascularization in breast cancer tissues. Cancer Lett. 171 (2001) 103-110
4. Maass N., Hojo T., Rösel F., Ikeda T., Jonat W., and Nagasaki K. Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. Clin. Biochem. 34 (2001) 303-307
5. Yasumatsu R., Nakashima T., Hirakawa N., Kumamoto Y., Kuratomi Y., Tomita K., and Komiyama S. Maspin expression in stage I and II oral tongue squamous cell carcinoma. Head Neck 23 (2001) 962-966
6. Shi H.Y., Liang R., Templeton N.S., and Zhang M. Inhibition of breast tumor progression by systemic delivery of the maspin gene in a syngenic tumor model. Mol. Ther. 5 (2002) 755-761
7. Khalkhali-Ellis Z. Maspin: the new frontier. Clin. Cancer Res. 12 (2006) 7279-7283
8. Khalkhali-Ellis Z., and Hendrix M.J. Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation. Cancer Res. 67 (2007) 3535-3539
9. Zhang M., Volpert O., Shi Y.H., and Bouck N. Maspin is an angiogenesis inhibitor. Nat. Med. 6 (2000) 196-199
10. Zou Z., Gao C., Nagaich A.K., Connell T., Saito S., Moul J.W., Seth P., Appella E., and Srivastava S. p53 regulates the expression of the tumor suppressor gene maspin. J. Biol. Chem. 275 (2000) 6051-6054
11. Domann F.E., Rice J.C., Hendrix M.J., and Futscher B.W. Epigenetic silencing of maspin gene expression in human breast cancers. Int. J. Cancer 85 (2000) 805-810
12. Futscher B.W., O'Meara M.M., Kim C.J., Rennels M.A., Lu D., Gruman L.M., Seftor R.E., Hendrix M.J., and Domann F.E. Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia 6 (2004) 380-389
13. Boltze C., Schneider-Stock R., Quednow C., Hinze R., Mawrin C., Hribaschek A., Roessner A., and Hoang-Vu C. Silencing of the maspin gene by promoter hypermethylation in thyroid cancer. Int. J. Mol. Med. 12 (2003) 479-484
14. Wada K., Maesawa C., Akasaka T., and Masuda T. Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. J. Invest. Dermatol. 122 (2004) 805-811
15. Bettstetter M., Woenckhaus M., Wild P.J., Rümmele P., Blaszyk H., Hartmann A., Hofstädter F., and Dietmaier W. Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J. Pathol. 205 (2005) 606-614
16. Beltran A.S., Sun X., Lizardi P.M., and Blancafort P. Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol. Cancer Ther. 7 (2008) 1080-1090
17. Umekita Y., and Yoshida H. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology 42 (2003) 541-545
18. Li Z., Shi H.Y., and Zhang M. Targeted expression of maspin in tumor vasculatures induces endothelial cell apoptosis. Oncogene 24 (2005) 2008-2019
19. Strimpakos A.S., and Sharma R.A. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid. Redox. Signal. 10 (2008) 511-545
20. Lev-Ari S., Lichtenberg D., and Arber N. Compositions for treatment of cancer and inflammation. Recent Patents. Anticancer Drug Discov. 3 (2008) 55-62
21. Clarke J.O., and Mullin G.E. A review of complementary and alternative approaches to immunomodulation. Nutr. Clin. Pract. 23 (2008) 49-62
22. Kunnumakkara A.B., Anand P., and Aggarwal B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269 (2008) 199-225
23. Kozuch P.L., and Hanauer S.B. Treatment of inflammatory bowel disease: a review of medical therapy. World J. Gastroenterol. 14 (2008) 354-377
24. Mehta K., Pantazis P., McQueen T., and Aggarwal B.B. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs 8 (1997) 470-481
25. Meeran S.M., and Katiyar S.K. Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front. Biosci. 13 (2008) 2191-2202
26. Huang M.T., Newmark H.L., and Frenkel K. Inhibitory effects of curcumin on tumorigenesis in mice. J. Cell. Biochem. Suppl. 27 (1997) 26-34
27. Huang M.T., Smart R.C., Wong C.Q., and Conney A.H. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 48 (1988) 5941-5946
28. Von Löw E.C., Perabo F.G., Siener R., and Müller S.C. Facts and fiction of phytotherapy for prostate cancer: a critical assessment of preclinical and clinical data. In Vivo 21 (2007) 189-204
29. Kunnumakkara A.B., Diagaradjane P., Guha S., Deorukhkar A., Shentu S., Aggarwal B.B., and Krishnan S. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin. Cancer Res. 14 (2008) 2128-2136
30. Wright T.I., Spencer J.M., and Flowers F.P. Chemoprevention of nonmelanoma skin cancer. J. Am. Acad. Dermatol. 54 (2006) 933-946
31. Sharma R.A., Steward W.P., and Gescher A.J. Pharmacokinetics and pharmacodynamics of curcumin. Adv. Exp. Med. Biol. 595 (2007) 453-470
32. Thangapazham R.L., Sharma A., and Maheshwari R.K. Beneficial role of curcumin in skin diseases. Adv. Exp. Med. Biol. 595 (2007) 343-357
33. Singh S., and Aggarwal B.B. Activation of transcription factor NF-kappaB is suppressed by curcumin (diferuloylmethane). J. Biol. Chem. 270 (1995) 24995-25000
34. Han S.S., Keum Y.S., Seo H.J., and Surh Y.J. Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J. Biochem. Mol. Biol. 35 (2002) 337-342
35. Bharti A.C., Shishodia S., Reuben J.M., Weber D., Alexanian R., Raj-Vadhan S., Estrov Z., Talpaz M., and Aggarwal B.B. Nuclear factor-B and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103 (2004) 3175-3184
36. Aggarwal S., Ichikawa H., Takada Y., Sandur S.K., Shishodia S., and Aggarwal B.B. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IB kinase and Akt activation. Mol. Pharmacol. 69 (2006) 195-206
37. Chen A., Xu J., and Johnson A.C. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 25 (2006) 278-287
38. Li M., Zhang Z., Hill D.L., Wang H., and Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 67 (2007) 1988-1996
39. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., Marczylo T.H., Morgan B., Hemingway D., Plummer S.M., Pirmohamed M., Gescher A.J., and Steward W.P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 10 (2004) 6847-6854
40. Bemis D.L., Katz A.E., and Buttyan R. Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin. Investig. Drugs 15 (2006) 1191-1200
41. Prasad C.P., Rath G., Mathur S., Bhatnagar D., and Ralhan R. Potent growth suppressive activity of curcumin in human breast cancer cells: modulation of Wnt/β-catenin signaling. Chemico-Biol Interac. 181 (2009) 263-271
42. Viale G. Histopathology of primary breast cancer 2003. Breast 12 (2003) 391-396
43. Mohsin S.K., Zhang M., Clark G.M., and Craig Allred D. Maspin expression in invasive breast cancer: association with other prognostic factors. J. Pathol. 199 (2003) 432-435
44. Bassarova A.V., Nesland J.M., Sedloev T., Lilleby W., Hristova S.L., Trifonov D.Y., and Torlakovic E. Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53. Int. J. Surg. Pathol. 13 (2005) 239-246
45. Rakha E.A., El-Sheikh S.E., Kandil M.A., El-Sayed M.E., Green A.R., and Ellis I.O. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum. Pathol. 39 (2008) 857-865
46. Bailey C.M., Khalkhali-Ellis Z., Seftor E.A., and Hendrix M.J. Biological functions of maspin. J. Cell. Physiol. 209 (2006) 617-624
47. Shi P., Chen W.W., Hu X.Y., Yu C.X., Zhang P.J., Jiang A.L., and Zhang J.Y. Up-regulates the expression of maspin gene in prostate cancer cell line LNCaP. Yao. Xue. Xue. Bao. 41 (2006) 1152-1156
48. Wang S.E., Narasanna A., Whitell C.W., Wu F.Y., Friedman D.B., and Arteaga C.L. Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. J. Biol. Chem. 282 (2007) 5661-5669
49. Choudhuri T., Pal S., Das T., and Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J. Biol. Chem. 280 (2005) 20059-20068
50. Sedic M., Poznic M., Gehrig P., Scott M., Schlapbach R., Hranjec M., Karminski-Zamola G., Pavelic K., and Kraljevic Pavelic S. Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-alpha]quinoline in colon cancer cells depending on their p53 status. Mol. Cancer Ther. 7 (2008) 2121-2132
51. Zhang W., Shi H.Y., and Zhang M. Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer 5 (2005) 50